Trials / Unknown
UnknownNCT00973505
CYP19 Genetic Polymorphism & Aromatase Inhibitor(AI)
Significance of CYP19 Genetic Polymorphism on Musculoskeletal Symptom & Complication of Aromatase Inhibitor(AI)
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- Korea University Anam Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the relationship between the side effects(especially arthralgia and arthritis) which appear in the patients who are prescribed aromatase inhibitor(AI) and the CYP19 genetic polymorphisms.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aromatase Inhibitor(Femara or Arimidex) | Femara(Letrozole) 2.5mg 1tab qd, Arimidex(Anastrozole) 1mg 1tab qd |
Timeline
- Start date
- 2009-03-01
- Primary completion
- 2010-09-01
- Completion
- 2010-09-01
- First posted
- 2009-09-09
- Last updated
- 2009-09-09
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT00973505. Inclusion in this directory is not an endorsement.